Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s): N.PFE

Healthcare

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Add To Watchlist

Recent & Breaking News (NYSE:PFE)

Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency

GlobeNewswire March 1, 2017

Pfizer Prices €4,000,000,000 Debt Offering

Business Wire February 28, 2017

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Business Wire February 28, 2017

FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review

PR Newswire Europe Non Regulatory February 28, 2017

Pfizer Prices $1,065,000,000 Debt Offering

Business Wire February 24, 2017

Ronald E. Blaylock Elected to Pfizer’s Board of Directors

Business Wire February 23, 2017

Investors: Option reports for Advanced Micro Devices, Macy's Incorporated, Nike, Pfizer Inc. and Vipshop Holdings

PR Newswire February 22, 2017

Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?

Benzinga.com February 21, 2017

Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration

Business Wire February 21, 2017

New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a

Business Wire February 17, 2017

Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab)

Business Wire February 16, 2017

Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers

Benzinga.com February 15, 2017

Relationship Expert Teams Up with Pfizer to Address Intimacy and Relationship Issues for People Living with Chronic Diseases

Business Wire February 9, 2017

Covered Call Reports for Cabot Oil and Gas Corp., Hasbro, Newell Brands Incorporated, Pfizer Inc., and Williams Companies from InvestorsObserver.

PR Newswire February 7, 2017

ICU Medical Completes the Acquisition of Hospira Infusion Systems from Pfizer

GlobeNewswire February 6, 2017

Pfizer Commences $5 Billion Accelerated Share Repurchase

Business Wire February 3, 2017

President Trump Doubles Down On Healthcare Criticism, Says Drug Prices Are 'Astronomical'

Benzinga.com January 31, 2017

Fed Meeting Starts Today, But Focus Remains On Key Earnings Data

Benzinga.com January 31, 2017

Healthcare Q4: Eli Lilly Beats, Pfizer Misses

Benzinga.com January 31, 2017

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2016 RESULTS

Business Wire January 31, 2017